{
    "matches": [
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Hepatobiliary disorders",
                    "Number of Grade 3 or 4 Adverse Events": "12",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "30.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[12, 30.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Hepatobiliary disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "12",
                    "30.0%"
                ]
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Hepatobiliary disorders",
                    "Number of Grade 3 or 4 Adverse Events": "15",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "25.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[15, 25.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Hepatobiliary disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "15",
                    "25.0%"
                ]
            },
            "match": "yes"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "7",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[7, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Respiratory and thoracic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "21.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 21.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "6",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "15.0%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[6, 15.0%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Blood and lymphatic disorders",
                    "Number of Grade 3 or 4 Adverse Events": "10",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[10, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Infections and infestations",
                    "Number of Grade 3 or 4 Adverse Events": "5",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "8.3%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[5, 8.3%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "3",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "7.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[3, 7.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Metabolism and nutrition disorders",
                    "Number of Grade 3 or 4 Adverse Events": "4",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "6.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[4, 6.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "9",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "17.5%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[9, 17.5%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Adverse Event SOC": "Other",
                    "Number of Grade 3 or 4 Adverse Events": "13",
                    "Percentage of Total Grade 3 or 4 Adverse Events": "16.7%"
                },
                "measures": "[Number of Grade 3 or 4 Adverse Events, Percentage of Total Grade 3 or 4 Adverse Events]",
                "outcomes": "[13, 16.7%]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients": "42",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "20",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "47.6%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients": "220",
                    "Number of Patients with \u22651 Grade 3 or 4 AE": "34",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE": "15.5%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-positive",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "11",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "26.2%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "17.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Infections and infestations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "9",
                    "15.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Gastrointestinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "8",
                    "13.3%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "5",
                    "12.5%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Investigations",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "7",
                    "11.7%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-positive"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "4",
                    "10.0%"
                ]
            },
            "match": "no"
        },
        {
            "Extracted_claim": {
                "subject": {
                    "Trial": "REMoxTB",
                    "Patient Group": "HIV-negative",
                    "Number of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "14",
                    "Percentage of Patients with \u22651 Grade 3 or 4 AE possibly related to treatment": "6.4%"
                },
                "measures": "[]",
                "outcomes": "[]"
            },
            "Ground_truth_claim": {
                "subject": {
                    "trial": "REMoxTB",
                    "population": "matched population",
                    "phase": "enrolment",
                    "comparison": "HIV-positive vs HIV-negative patients",
                    "event severity": "Grade 3 or 4",
                    "event type": "Adverse Events (AEs)",
                    "filter": "five most frequently reported SOCs",
                    "system organ class (SOC)": "Respiratory, thoracic and mediastinal disorders",
                    "HIV status": "HIV-negative"
                },
                "measures": [
                    "Count",
                    "Percentage of G3+ Events"
                ],
                "outcomes": [
                    "6",
                    "10.0%"
                ]
            },
            "match": "no"
        }
    ],
    "total_extracted_claims": 16,
    "total_ground_truth_claims": 10,
    "number_of_matches": 2
}